骨肉瘤保肢治疗的进展
Advances in limb salvage treatment of osteosarcoma.
作者信息
Yang Yichun, Han Lei, He Zewei, Li Xiaojuan, Yang Suping, Yang Jifei, Zhang Ya, Li Dongqi, Yang Yihaho, Yang Zuozhang
机构信息
Department of Medical, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No 16, Jichang Road, Baiyun District, Guangzhou, Guangdong 510405, People's Republic of China.
Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, People's Republic of China.
出版信息
J Bone Oncol. 2017 Nov 26;10:36-40. doi: 10.1016/j.jbo.2017.11.005. eCollection 2018 Mar.
Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.
骨肉瘤是最常见的原发性恶性骨肿瘤；其标准治疗包括新辅助化疗联合手术。自19世纪70年代以来，新辅助化疗显著提高了骨肉瘤患者的5年生存率和保肢率。保肢患者的生存率不低于截肢患者，因此，保肢已成为骨肉瘤患者的主要手术选择。骨肉瘤的5年生存率已趋于平稳。然而，目前骨肉瘤保肢治疗有了新进展，包括辅助化疗、消融技术、骨搬运技术和计算机导航技术。本报告总结了过去十年骨肉瘤保肢治疗的最新进展。
Zotero 插件